Moomoo AI 已提取核心信息
On January 31, 2024, HOOKIPA Pharma Inc. received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. This move is part of the company's strategy to regain compliance with Nasdaq's minimum bid price requirement. HOOKIPA Pharma's stock had previously fallen below the $1.00 minimum bid price for 30 consecutive business days, leading to a notification of non-compliance. The company was initially given a 180-day grace period to meet the requirement, which it did not achieve. The transfer to The Nasdaq Capital Market allows HOOKIPA Pharma an additional 180-day period, ending on July 29, 2024, to demonstrate compliance. During this time, the company must maintain a closing bid price of at least $1.00 for 10 consecutive business days. HOOKIPA Pharma has indicated that it may consider a reverse stock split as a potential solution to address the bid price deficiency if necessary. The company's common stock will continue to trade under the ticker symbol 'HOOK'.
On January 31, 2024, HOOKIPA Pharma Inc. received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. This move is part of the company's strategy to regain compliance with Nasdaq's minimum bid price requirement. HOOKIPA Pharma's stock had previously fallen below the $1.00 minimum bid price for 30 consecutive business days, leading to a notification of non-compliance. The company was initially given a 180-day grace period to meet the requirement, which it did not achieve. The transfer to The Nasdaq Capital Market allows HOOKIPA Pharma an additional 180-day period, ending on July 29, 2024, to demonstrate compliance. During this time, the company must maintain a closing bid price of at least $1.00 for 10 consecutive business days. HOOKIPA Pharma has indicated that it may consider a reverse stock split as a potential solution to address the bid price deficiency if necessary. The company's common stock will continue to trade under the ticker symbol 'HOOK'.
2024年1月31日，HOOKIPA Pharma Inc.获得纳斯达克批准，将其普通股的上市从纳斯达克全球精选市场转移到纳斯达克资本市场。此举是该公司恢复遵守纳斯达克最低出价要求的战略的一部分。HOOKIPA Pharma的股票此前已连续30个工作日跌破1.00美元的最低出价，这导致了违规通知。该公司最初有180天的宽限期来满足该要求，但它没有实现这一要求。向纳斯达克资本市场的转让允许HOOKIPA Pharma再有180天的时间来证明合规性，该期限将于2024年7月29日结束。在此期间，公司必须连续10个工作日将收盘价维持在至少1.00美元。HOOKIPA Pharma表示，如有必要，它可能会考虑将反向股票拆分作为解决出价缺陷的潜在解决方案。该公司的普通股将继续以股票代码 “HOOK” 进行交易。
2024年1月31日，HOOKIPA Pharma Inc.获得纳斯达克批准，将其普通股的上市从纳斯达克全球精选市场转移到纳斯达克资本市场。此举是该公司恢复遵守纳斯达克最低出价要求的战略的一部分。HOOKIPA Pharma的股票此前已连续30个工作日跌破1.00美元的最低出价，这导致了违规通知。该公司最初有180天的宽限期来满足该要求，但它没有实现这一要求。向纳斯达克资本市场的转让允许HOOKIPA Pharma再有180天的时间来证明合规性，该期限将于2024年7月29日结束。在此期间，公司必须连续10个工作日将收盘价维持在至少1.00美元。HOOKIPA Pharma表示，如有必要，它可能会考虑将反向股票拆分作为解决出价缺陷的潜在解决方案。该公司的普通股将继续以股票代码 “HOOK” 进行交易。
有用
没用